2. Mergers and acquisitions are picking up: So far this year, buyouts have boosted several biotech stocks. Some standouts: ...

Federal regulators are trying to make it easier to develop cheaper alternatives to powerful drugs that many Americans depend ...

Alexandria Real Estate Equities, Inc. faces ongoing headwinds, with soft biotech demand, and declining occupancy. Learn more ...

Acquisition talks for Metsera that played out this year culminated in an agreement with Pfizer, which agreed to buy the ...

Cytokinetics (CYTK) shares have moved in line with broader biotech trends, as investors pay close attention to recent performance data. Over the past month, the stock has climbed 15%, reflecting ...

The deal, which enables patients to pick up orders placed through Lilly’s online channel at Walmart pharmacies, is the latest ...

Brian McNamee, the man who transformed CSL from a sleepy government department to one of Australia’s largest companies, has ...

Australian biotech giant CSL has delayed its vaccine division spin-off due to a drastic decline in US flu immunization rates, leading to a 16.6% drop in share price. The company's revenue and profit ...

Learn more about whether ADMA Biologics, Inc. or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor ...

The pharmaceutical giant has avoided a board spill, but 42 per cent of shareholders voted against executive remuneration in a ...

Learn more about whether Alvotech or Arcus Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Life sciences giant Thermo Fisher Scientific has agreed to acquire clinical trials software company Clario for a consideration of up to $9.4bn.